A302440 Stock Overview
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally.
No risks detected for A302440 from our risk checks.
SK bioscienceLtd Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩121,500.00|
|52 Week High||₩362,000.00|
|52 Week Low||₩115,000.00|
|1 Month Change||-10.99%|
|3 Month Change||-19.27%|
|1 Year Change||-24.77%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-28.11%|
Recent News & Updates
|A302440||KR Biotechs||KR Market|
Return vs Industry: A302440 exceeded the KR Biotechs industry which returned -38% over the past year.
Return vs Market: A302440 underperformed the KR Market which returned -14.6% over the past year.
|A302440 Average Weekly Movement||6.6%|
|Biotechs Industry Average Movement||6.6%|
|Market Average Movement||5.6%|
|10% most volatile stocks in KR Market||10.4%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A302440 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: A302440's weekly volatility (7%) has been stable over the past year.
About the Company
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.
SK bioscienceLtd Fundamentals Summary
|A302440 fundamental statistics|
Is A302440 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A302440 income statement (TTM)|
|Cost of Revenue||₩358.97b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||4.63k|
|Net Profit Margin||38.23%|
How did A302440 perform over the long term?See historical performance and comparison
Is SK bioscienceLtd undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: A302440 (₩121500) is trading below our estimate of fair value (₩221704.11)
Significantly Below Fair Value: A302440 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: A302440 is poor value based on its PE Ratio (26.3x) compared to the KR Biotechs industry average (25.4x).
PE vs Market: A302440 is poor value based on its PE Ratio (26.3x) compared to the KR market (14.4x).
Price to Earnings Growth Ratio
PEG Ratio: A302440 is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: A302440 is overvalued based on its PB Ratio (5.8x) compared to the KR Biotechs industry average (3.3x).
How is SK bioscienceLtd forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A302440's forecast earnings growth (19.4% per year) is above the savings rate (3.5%).
Earnings vs Market: A302440's earnings (19.4% per year) are forecast to grow faster than the KR market (14.8% per year).
High Growth Earnings: A302440's earnings are forecast to grow, but not significantly.
Revenue vs Market: A302440's revenue (18.3% per year) is forecast to grow faster than the KR market (9.6% per year).
High Growth Revenue: A302440's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A302440's Return on Equity is forecast to be low in 3 years time (15.1%).
How has SK bioscienceLtd performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: A302440 has high quality earnings.
Growing Profit Margin: A302440's current net profit margins (38.2%) are higher than last year (14.6%).
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A302440's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A302440's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: A302440 earnings growth over the past year (979.8%) exceeded the Biotechs industry 37.5%.
Return on Equity
High ROE: A302440's Return on Equity (22.2%) is considered high.
How is SK bioscienceLtd's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A302440's short term assets (₩1,837.8B) exceed its short term liabilities (₩460.0B).
Long Term Liabilities: A302440's short term assets (₩1,837.8B) exceed its long term liabilities (₩48.9B).
Debt to Equity History and Analysis
Debt Level: A302440 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A302440's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: A302440's debt is well covered by operating cash flow (563.9%).
Interest Coverage: A302440's interest payments on its debt are well covered by EBIT (248.2x coverage).
What is SK bioscienceLtd current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A302440's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A302440's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A302440's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A302440's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A302440 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jae-Yong Ahn (54 yo)
Mr. Jae-Yong Ahn is the Chairman, Chief Executive Officer and President of SK bioscience Co.,Ltd since March 2021. He serves as Executive Officer and Director of VAX Business Division at SK Discovery Co.,...
Experienced Board: A302440's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
SK bioscience Co.,Ltd.'s employee growth, exchange listings and data sources
- Name: SK bioscience Co.,Ltd.
- Ticker: A302440
- Exchange: KOSE
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩9.598t
- Shares outstanding: 76.78m
- Website: https://www.skbioscience.co.kr
- SK bioscience Co.,Ltd.
- 310, Pangyo-ro
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.